[go: up one dir, main page]

NO20085259L - Framgangsmate - Google Patents

Framgangsmate

Info

Publication number
NO20085259L
NO20085259L NO20085259A NO20085259A NO20085259L NO 20085259 L NO20085259 L NO 20085259L NO 20085259 A NO20085259 A NO 20085259A NO 20085259 A NO20085259 A NO 20085259A NO 20085259 L NO20085259 L NO 20085259L
Authority
NO
Norway
Prior art keywords
cell
sirna molecule
carrier
photosensitizer
kits
Prior art date
Application number
NO20085259A
Other languages
English (en)
Other versions
NO342202B1 (no
Inventor
Sigurd Boe
Eivind Johannes Hovig
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of NO20085259L publication Critical patent/NO20085259L/no
Publication of NO342202B1 publication Critical patent/NO342202B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse vedrører en fremgangsmåte for innføring av et siRNA-molekyl inn i cytosolen til en celle, idet framgangsmåten omfatter i) å bringe cellen i kontakt med et siRNA-mo lekyl, en bærer og et fotosensibiliseringsmiddel, og ii) å bestråle cellen med lys av en bølgelengde som er effektiv til å aktivere fotosensibiliseringsmidlet, hvori bæreren omfatter et kationisk polyamin slik som et lipopolyamin i en ikke- liposomal formulering, et polyetylenimin (PEI", en betasyklodekstrinaminpolymer, en dendrimer som inneholder en aminogruppe, eller et kationisk peptid. Celler eller populasjoner av celler som kan framskaffes ved framgangsmåten, preparat som inneholder et siRNA- molekyl og bærermolekylet, sett (kits) og terapeutiske anvendelser av ovennevnte stilles også til rådighet.
NO20085259A 2006-07-11 2008-12-16 Framgangsmåte for innføring av siRNA i celler ved fotokjemisk internalisering NO342202B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0613753.3A GB0613753D0 (en) 2006-07-11 2006-07-11 Method
PCT/GB2007/002569 WO2008007073A2 (en) 2006-07-11 2007-07-11 Method for introducing sirna into cells by photochemical internalisation

Publications (2)

Publication Number Publication Date
NO20085259L true NO20085259L (no) 2009-02-10
NO342202B1 NO342202B1 (no) 2018-04-16

Family

ID=36955439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085259A NO342202B1 (no) 2006-07-11 2008-12-16 Framgangsmåte for innføring av siRNA i celler ved fotokjemisk internalisering

Country Status (15)

Country Link
US (2) US20090297487A1 (no)
EP (1) EP2037962B1 (no)
JP (1) JP5269783B2 (no)
CN (1) CN101573140B (no)
AU (1) AU2007274056B2 (no)
CA (1) CA2657999C (no)
DK (1) DK2037962T3 (no)
ES (1) ES2525222T3 (no)
GB (1) GB0613753D0 (no)
NO (1) NO342202B1 (no)
NZ (1) NZ573775A (no)
PL (1) PL2037962T3 (no)
RU (1) RU2510826C2 (no)
WO (1) WO2008007073A2 (no)
ZA (1) ZA200810684B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
US20100297756A1 (en) * 2007-12-13 2010-11-25 Abdennajj Adib Means for delivery of nucleic acids active for gene silencing using synthetic polymers
WO2009109862A2 (en) * 2008-03-06 2009-09-11 Rolf Lewensohn Improved cancer therapeutics
US20100056475A1 (en) * 2008-08-06 2010-03-04 Alexander Chucholowski Cyclodextrin conjugates
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
CN101831046B (zh) * 2010-03-30 2012-10-31 上海交通大学 交联剂和聚氨酯硬质泡沫材料及其制备方法
WO2012005572A1 (en) 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
ES2688619T3 (es) 2011-12-22 2018-11-05 Interna Technologies B.V. MiARN para tratar el cáncer de cabeza y de cuello
WO2013109983A1 (en) * 2012-01-18 2013-07-25 University Of Utah Research Foundation High molecular wieght arginine-grafted bioreducible polymers
US9677078B2 (en) * 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
EP3800256A1 (en) 2012-11-06 2021-04-07 InteRNA Technologies B.V. Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
JP6462681B2 (ja) 2013-07-12 2019-01-30 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィーのインプットの最適化の解明
KR102374556B1 (ko) * 2013-08-28 2022-03-14 피씨아이 바이오테크 에이에스 백신접종 및 면역화를 위한 화합물 및 방법
EP3034539A1 (en) * 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
CN104878044B (zh) * 2015-04-29 2018-07-17 常州百代生物科技有限公司 一种脂类化合物siRNA转染试剂
WO2017191219A1 (en) * 2016-05-05 2017-11-09 Cosmophos Ltd Nano-systems for therapy and/or diagnosis and/or therapy monitoring and/or theranostics of disease
CN106924746B (zh) * 2017-03-03 2020-11-03 中山大学 复合基因载体及其应用
CN107011511B (zh) * 2017-06-01 2019-04-26 西南大学 一种原卟啉荧光碳点及制备方法和应用
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
JP2021501594A (ja) 2017-11-03 2021-01-21 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． ニューロンの欠損に関連する状態及び／又は疾患を処置及び／又は診断するため、或いはニューロンの再生／発生のための、ｍｉＲＮＡ分子、等価物、アンタゴミル、又はそれらの供給源
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
EP3793616A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3807404A1 (en) 2018-06-13 2021-04-21 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
EP3826719A1 (en) 2018-07-24 2021-06-02 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
CA3115248A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
JP2022505106A (ja) 2018-10-15 2022-01-14 ボイジャー セラピューティクス インコーポレイテッド バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
US20220064671A1 (en) 2019-01-18 2022-03-03 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN114452406B (zh) * 2022-03-16 2023-05-23 安徽工程大学 一种抑菌材料及其制备方法和应用
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2023417630A1 (en) 2022-12-29 2025-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
CN118207158B (zh) * 2023-06-21 2024-08-27 天津医科大学眼科医院 一种细胞内来源的纳米囊泡的制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
RU2066552C1 (ru) 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
ES2445579T3 (es) 2000-11-29 2014-03-04 Pci Biotech As Internalización fotoquímica para el suministro de moléculas mediado por virus en el citosol
US7223600B2 (en) * 2000-11-29 2007-05-29 The Norwegian Radium Hospital Research Foundation Photochemical internalization for delivery of molecules into the cytosol
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
CA2500468A1 (en) * 2002-09-28 2004-04-08 Massachussets Institute Of Technology Influenza therapeutic
CA2506714A1 (en) * 2002-11-26 2004-06-10 University Of Massachusetts Delivery of sirnas
FR2858628B1 (fr) 2003-08-04 2008-01-04 Polyplus Transfection Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method

Also Published As

Publication number Publication date
AU2007274056A1 (en) 2008-01-17
AU2007274056B2 (en) 2013-08-01
ZA200810684B (en) 2010-08-25
CA2657999C (en) 2015-02-24
PL2037962T3 (pl) 2015-03-31
GB0613753D0 (en) 2006-08-23
JP2010504080A (ja) 2010-02-12
CN101573140B (zh) 2014-04-23
US9700622B2 (en) 2017-07-11
WO2008007073A2 (en) 2008-01-17
NO342202B1 (no) 2018-04-16
US20090297487A1 (en) 2009-12-03
NZ573775A (en) 2012-11-30
CN101573140A (zh) 2009-11-04
RU2510826C2 (ru) 2014-04-10
DK2037962T3 (en) 2014-12-15
ES2525222T3 (es) 2014-12-19
JP5269783B2 (ja) 2013-08-21
WO2008007073A3 (en) 2008-04-10
EP2037962A2 (en) 2009-03-25
CA2657999A1 (en) 2008-01-17
US20120264807A1 (en) 2012-10-18
RU2008150847A (ru) 2010-06-27
EP2037962B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
NO20085259L (no) Framgangsmate
Gao et al. Bacteria‐targeted supramolecular photosensitizer delivery vehicles for photodynamic ablation against biofilms
Lakshmanan et al. Rapid and efficient gene delivery into plant cells using designed peptide carriers
Wei et al. Bridging adhesion of mussel-inspired peptides: role of charge, chain length, and surface type
Manickam et al. Multiblock reducible copolypeptides containing histidine-rich and nuclear localization sequences for gene delivery
BR112013030432A2 (pt) método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos
Abul‐Haija et al. Biocatalytically Triggered Co‐Assembly of Two‐Component Core/Shell Nanofibers
Scholz et al. Correlation of length of linear oligo (ethanamino) amides with gene transfer and cytotoxicity
Choi et al. Multifunctional siRNA delivery system: Polyelectrolyte complex micelles of six‐arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide
BRPI0409911A (pt) método para liberar uma molécula em uma célula, e, complexo carreador
WO2008079973A9 (en) Egfr binding peptides and uses thereof
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
WO2013009475A8 (en) Photosensitizing antibody-fluorophore conjugates
CL2008001814A1 (es) Anticuerpos anti-factor de crecimiento 1 y 2 semejantes a insulina (igf-1, igf-2); molecula de adn que los codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que los comprende; y su uso para tratar cancer.
Lim et al. Polydopamine adhesion: catechol, amine, dihydroxyindole, and aggregation dynamics
PE20091388A1 (es) Moleculas y metodos para modular el componente de complemento
Tu et al. Computational Investigations of a Peptide‐Modified Dendrimer Interacting with Lipid Membranes
Nakamura et al. DNA‐modified artificial viral capsids self‐assembled from DNA‐conjugated β‐annulus peptide
Du et al. Property regulation of conjugated oligoelectrolytes with polyisocyanide to achieve efficient photodynamic antibacterial biomimetic hydrogels
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
Bechara et al. MALDI-TOF mass spectrometry analysis of amphipol-trapped membrane proteins
Kong et al. Photo-and aromatic stacking-induced green emissive peptidyl nanoparticles for cell imaging and monitoring of nucleic acid delivery
Holley et al. Endolytic, pH-responsive HPMA-b-(l-Glu) copolymers synthesized via sequential aqueous RAFT and ring-opening polymerizations
Webster et al. Discovery of a Peptoid-Based Nanoparticle Platform for Therapeutic mRNA Delivery via Diverse Library Clustering and Structural Parametrization
GB0415263D0 (en) Method

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees